Development of Lewy Bodies Biofluid Signatures by Targeted Proteomics (U18)

Vlad Petyuk
Pacific Northwest National Laboratory

November 12, 2012

NINDS



PNNL Proteomics

 Biological Sciences Division

Related Resources

Matthew Monroe

Christine Sharp

Contacts

WebMaster

Sponsors

Content



Proteomics Research Center Proteomics

About Us

- Technology Development
- Proteomics Process
- Instrumentation Collaborations
 - Collaborations
 - Staff
 - Access
 - Location
 - Links to offsite websites

The Proteomics Research Resource for Integrative Biology is a national user facility established and funded by the National Institute of

This Center has been established to serve the biomedical research community by developing and integrating new proteomic technologies for collaborative and service studies, disseminating the new technologies, and training scientists in their use.

Housed in the William R. Wiley Environmental Molecular Sciences Laboratory (EMSL), the Center leverages and extends the substantial capabilities of the EMSL that presently include a collaboratory infrastructure, unique mass spectrometric instrumentation, and a powerful suite of proteomic data management and analysis tools.

The EMSL is a U.S. Department of Energy user facility located on the campus of Pacific Northwest National Laboratory (PNNL), PNNL is a multi-disciplinary laboratory where scientists and engineers resolve critical challenges in energy, the environment, and national security,

- Quantitative Bottom-up LC-MS proteomics
 - Large scale (> 1,000 samples) studies
 - Post-translational modifications:
 - Phosphoproteomics: pS/T, pY
 - Glycosylation: N-GlcNAc, O-GlcNAc
 - Glycation: advanced glycation endproducts (AGE)
 - Oxidative damage: methionine oxidation, tyrosine nitration
 - Top-down analysis of intact proteins
 - Protein isoforms
 - Combinations of posttranslational modifications
 - Proteolytic fragments
 - Protein turnover
 - Activity-based proteomics
 - Targeted SRM quantitation of lowabundant proteins







Posters and Presentations

Training & Protocols

Contacts

About Us

Data

Software & Tools

News & Events

Publications

Collaborative Research - NEW Career Area

Lifestyle & Community






PNNL Home | About | Research | Publications | Jobs | Newsroom | Contacts | Search PNNL



Proudly Operated by Battelle Since 1965



Lewy Bodies




Photomicrographs of regions of substantia nigra in this Parkinson's patient show Lewy bodies and Lewy neurites in various magnifications. Top panels show a 60-times magnification of the alpha-synuclein intraneuronal inclusions aggregated to form Lewy bodies. The bottom panels are 20x magnification images that show strand-like Lewy neurites and rounded Lewy bodies of various sizes. Neuromelanin-laden cells of the substantia nigra are visible in the background.

http://en.wikipedia.org/wiki/Lewy_body

Pacific Northwest

The Premises for Successful Development of Biofluid Biomarkers

- There are differences in abundances of proteins, their isoforms or posttranslationally modified forms between LB-containing and LB-free brain tissue specimens.
- Those proteins/isoforms/modifications are:
 - Brain or even brain-region specific (thus avoiding dilution issue)
 - > 2-fold Increase in abundance in the case of pathologic condition (debatable)
 - Infiltrate the blood with reasonable efficiency (i.e. either highly abundant or effectively secreted)





Specific Aims

- 1. Identify proteins that correlate with the presence of the Lewy bodies in brain tissue. We will perform statistical analysis of quantitative LC-MS proteomics data that represents brain tissue samples of 500 subjects from the Religious Orders Study (ROS) and Memory and Aging Project (MAP) cohorts. Proteins that exhibit significant increases in abundance associated with the presence of Lewy bodies and are expressed exclusively in the brain tissue will be considered as biomarker candidates for subsequent verification in the CSF and blood.
- **2.** Verify the measured abundances of putative LB biomarkers in CSF and blood serum biofluids, correlate the results with brain tissue abundances within the same subjects, and develop a predictive model for LB presence. We will measure extremely low levels of brain specific proteins in CSF and blood serum by taking advantage of a recently developed ultrasensitive SRM approach. We will select proteins that show statistically significant correlations between the abundance profiles for brain tissue and the corresponding biofluid. Selected biomarkers will be utilized to develop a statistical model for predicting the LB load in the brain.
- **3. Validate the blood-based LB predictive model using an independent PD case/control cohort.** Protein biomarkers will be quantified in serum from 20 PD patients and matched controls available from the Osteoporotic Fractures in Men Study (MrOS) cohort. The predictions derived from the model will be matched against the clinical data to assess the agreement.
- Statement of Impact. The proposed project fundamentally aims to understand the relationships between protein abundance profiles in brain and biofluids such as CSF and blood. Reflection of the brain proteome in these biofluids would open a path for biomarker development for a number of neurodegenerative and other brain-related disorders. The successful outcome of the project will demonstrate the feasibility of following-up brain specific proteins in the CSF and especially in blood via ultra-sensitive SRM technology. A specific outcome of the project includes a statistical model for predicting LB load based on protein abundances in either blood serum or CSF, or both biofluids. We believe that the biofluid based LB assay will be a valuable addition to the toolbox for diagnostics and drug trials.

Ongoing Collaboration



David Bennett Rush University


Director of Rush Alzheimer's Disease Center.
Longitudinal studies of ageonset brain disorders and cognitive impairment. ~3,000 participants. Post-mortem organ donation.

500 well-characterized frontal gyrus brain tissue samples



Amanda Myers University of Miami

Population genetics




5R01AG034504BRAINOME: Genome, transcriptome and proteome interaction in human cortex.




Vlad Petyuk
Pacific Northwest National Lab

Proteomics







Proudly Operated by Battelle Since 1965





Experimental Design for Protein Quantitation Across 982 Brain Tissue Samples



Peptide Identification by Mass and Elution Time








C	PEPTIDE	MASS	NET	∆MASS (PPM)	ΔNET
	ITPELLTR	941.5545	0.2923	-1045.8	<u>0.015</u>
	SGKPAELLK	941.5545	0.2285	-1045.8	-0.049
	VLQIVTNR	941.5658	0.2487	-1033.9	-0.029
	RAVSQLIR	941.5770	0.2446	-1022.0	-0.033
	FFEQMQN	942.3905	0.2857	-157.8	<u>0.008</u>
	HELIEFR	942.4923	0.3087	-49.8	0.031
	<u>LTVPSADLK</u>	942.5385	0.2659	<u>-0.7</u>	<u>-0.012</u>
	TMYQVFR	943.4585	0.3033	974.4	0.026
	HMLPSGFR	943.4698	0.2719	986.3	<u>-0.006</u>
	LACGVIGIAQ	943.5160	0.3202	1035.3	0.042
	AGLQFPVGR	943.5239	0.3150	1043.6	0.037
	SATLFIHR	943.5239	0.2753	1043.6	<u>-0.002</u>
	RGNVIMVR	943.5385	0.2349	1059.1	-0.043

Reasonable tolerances are:

- 2 ppm in mass measurement
- 0.02 deviation in elution time

Acquired Proteomics Datasets




Sample Group	#
Pooled Controls	88
EURAD	93
EURCON	45
MAP	191
ROS	297
UKAD	65
UKCON	73
WGAAD	35
WGACON	82

*) Peptides for corresponding proteins required to be consistently present in at least 50% of pooled controls samples




Differential Abundance Between Low and High NIA-Reagan Scores





UniProt	p.vals		FDR	e.vals	Log2 Ratio
A4_HUMAN		1.29E-11	1.37E-08	1.37E-08	1.257504
GFAP_HUMAN		8.92E-05	4.75E-02	9.50E-02	0.244635
KPCE_HUMAN		1.58E-04	5.60E-02	1.68E-01	0.135608
NDUS5_HUMAN		4.43E-04	1.18E-01	4.71E-01	0.444904
TLN2_HUMAN		7.45E-04	1.59E-01	7.93E-01	0.387727



Differential Abundance Between Subject With and Without Lewy Bodies








Gene	UniProt	p.vals	FDR	e.vals	Log2 Ratio	fold
UQCRC2	QCR2_HUMAN	5.32E-05	0.055733	0.055733	-0.58351	0.66
GNAI1	GNAI1_HUMAN	4.93E-04	0.258156	0.516311	-0.48109	0.71
PGK1	PGK1_HUMAN	5.86E-04	0.204765	0.614295	0.098997	1.07
SELENBP1	SBP1_HUMAN	9.35E-04	0.245086	0.980345	0.912769	1.87





Tissue Specificity of Differentially Abundant Proteins




First month update: No good candidates, yet.

To Do:

- 1) Statistical analysis accounting for confounding factors such as (sex, age, PMI and other pathologies).
- 2) Explore post-translational modifications



Main and Alternative Paths of the Project




Quote from the summary statement:

"Along these lines, the panel suggested that, in addition to cortical LB, LB in brain stem and substantia nigra should be included in the brain marker evaluation."



Distribution of LB Across Different Brain Regions



sn – substantia nigra


ec – entorhinal cortex

acc – anterior cingulate cortex

mtc – middle temporal gyrus

mfc – frontal gyrus


ag – angular gyrus





Study Design (Aim 1)

Case – Control Design




List of proteins, isoforms or post-translational modifications increased (or even appeared) in LB+ group.

Next Qualification Step: Ensure SN (LB-containing SN) specificity of the discovered protein or proteoform candidates.

- a) In the case of protein: Querying gene expression databases
- b) In the case of proteoforms: Limited (top-down or targeted) LC-MS analysis of other abundant tissues

The Outcome of Top-Down Proteomics Experiments





Acknowledgements

University of Miami Amanda Myers Victor Andreev

Rush University David Bennett



PNNL
Dick Smith & Co.
Paul Piehowski
Fang Xie
Danny Orton

